Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet designed to treat obesity and other metabolic disorders. The sharp downturn, which saw the company's shares plummet by over 30% in early trading,
The obesity treatment market is exploding, with Goldman Sachs projecting it to reach $130 billion by 2030. Driven by rising global obesity rates—now at 42% of U.S. adults, per the CDC—the sector has become a magnet for investors seeking exposure to transformative medicine.
In the face of a frothy market, Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market's irrationality.
